Cargando…
Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab
The IL-17A inhibitor secukinumab is efficacious for the treatment of psoriasis. To better understand its mechanism of action, we investigated its impact on psoriatic lesions from 15 patients with moderate-to-severe plaque psoriasis undergoing secukinumab treatment. We characterized the longitudinal...
Autores principales: | Liu, Jared, Chang, Hsin-Wen, Grewal, Robby, Cummins, Daniel D., Bui, Audrey, Beck, Kristen M., Sekhon, Sahil, Yan, Di, Huang, Zhi-Ming, Schmidt, Timothy H., Yang, Eric J., Sanchez, Isabelle M., Nakamura, Mio, Bhattarai, Shrishti, Thibodeaux, Quinn, Ahn, Richard, Pauli, Mariela, Bhutani, Tina, Rosenblum, Michael D., Liao, Wilson |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214344/ https://www.ncbi.nlm.nih.gov/pubmed/35757784 http://dx.doi.org/10.1016/j.xjidi.2021.100094 |
Ejemplares similares
-
Chronic erythema nodosum with koebnerization to plaque psoriasis()()
por: Smith, Mary Patricia, et al.
Publicado: (2019) -
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017) -
Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019) -
Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020) -
Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
por: Ikuma, Daiuske, et al.
Publicado: (2019)